Skip to main content

Endometrial Cancer Clinical Trials

Review the endometrial cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 101-125 of 166

E7777 and Pembrolizumab for the Treatment of Patients with Recurrent or Metastatic Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
ALG.APV-527 First-in-human Study
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Personalized Neoantigen Peptide-Based Vaccine in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Hypofractionated Radiation Therapy with Adaptive Planning for the Treatment of Endometrial and Cervical Cancer, HERA Trial
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Zanzalintinib in Combination with Paclitaxel for the Treatment of Recurrent High Grade Uterine Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Combination ONC201 and Atezolizumab for the Treatment of Metastatic or Recurrent Obesity-Driven Endometrial Cancer
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Tumor Treating Fields Therapy in Combination with Chemotherapy for the Treatment of Advanced Solid Tumors Involving the Abdomen or Thorax
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
IACS-6274 with or without Bevacizumab and Paclitaxel or Capivasertib for the Treatment of Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
Status: Active
Location: Northwestern University, Chicago, Illinois
FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
A Study of MGC026 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Physical Therapy and Coping Skills Training for Improving Women's Sexual Function after Pelvic Radiation
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies
Status: Active
Location: See ClinicalTrials.gov
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Status: Active
Location: See ClinicalTrials.gov
A Study Evaluating MM-310 in Patients With Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies
Status: Active
Location: See ClinicalTrials.gov
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
Status: Temporarily Closed to Accrual
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Niraparib and Copanlisib in Treating Patients with Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Selumetinib and Olaparib in Treating Participants with Relapsed or Refractory and Advanced Endometrial, Ovarian, or Other Solid Tumors with RAS Pathway Alterations
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Distance-Based Exercise to Preserve Function and Prevent Disability (DEFEND)
Status: Active
Location: 17 locations